UPDATE: Aptose Biosciences (APTO) PT Raised to $9 at Oppenheimer on Luxeptinib Ph1 Trial Data
Tweet Send to a Friend
(Updated - March 24, 2021 9:15 AM EDT)
Oppenheimer analyst Matthew Biegler raised the price target on Aptose Biosciences ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Oppenheimer analyst Matthew Biegler raised the price target on Aptose Biosciences ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
